文献速递乳腺癌

激活型ESR1突变对ER拮抗剂疗效的差异影响

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
PubMed 文献 · Cancer Discov · 2016-12-16

研究对900余例转移性乳腺癌患者进行ESR1突变谱分析,突变检出率10%,D538G最常见(36%),其次Y537S(14%)。多数突变导致受体组成性激活并降低对ER拮抗剂的敏感性,但仅Y537S等特定突变在体内引起与氟维司群耐药相关的改变;Y537S驱动的肿瘤对氟维司群抑制效果较差,而对AZD9496等更强效、生物利用度更高的拮抗剂更敏感。

要点

  • 转移性乳腺癌患者ESR1突变检出率10%,D538G占36%、Y537S占14%。
  • 多数ESR1突变导致组成性激活并降低对ER拮抗剂的敏感性,但仅特定突变如Y537S在体内引起与氟维司群耐药相关的改变。
  • Y537S驱动的肿瘤对氟维司群抑制效果较差,对AZD9496等更强效拮抗剂更敏感。

核心结论

  • ESR1激活型突变存在多样性,仅部分突变导致对现有ER拮抗剂耐药,可能被AZD9496等下一代抑制剂克服。

研究设计与样本

  • 研究对900余例患者的ESR1突变谱进行表征。

主要发现

  • ESR1突变检出率为10%,D538G最常见(36%),其次为Y537S(14%)。
  • 还检测到新的激活型突变,如L469V、V422del和Y537D。
  • 多数突变导致组成性激活并降低对ER拮抗剂的敏感性,但仅特定突变如Y537S在体内引起与氟维司群耐药相关的改变。
  • Y537S驱动的肿瘤对氟维司群的抑制效果低于更强效、生物利用度更高的拮抗剂(包括AZD9496),而D538G、E380Q或S463P驱动的肿瘤无此差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent studies have identified somatic ESR1 mutations in patients with metastatic breast cancer and found some of them to promote estrogen-independent activation of the receptor. The degree to which all recurrent mutants can drive estrogen-independent activities and reduced sensitivity to ER antagonists like fulvestrant is not established. In this report, we characterize the spectrum of ESR1 mutations from more than 900 patients. ESR1 mutations were detected in 10%, with D538G being the most frequent (36%), followed by Y537S (14%). Several novel, activating mutations were also detected (e.g., L469V, V422del, and Y537D). Although many mutations lead to constitutive activity and reduced sensitivity to ER antagonists, only select mutants such as Y537S caused a magnitude of change associated with fulvestrant resistance in vivo Correspondingly, tumors driven by Y537S, but not D5358G, E380Q, or S463P, were less effectively inhibited by fulvestrant than more potent and bioavailable antagonists, including AZD9496. These data point to a need for antagonists with optimal pharmacokinetic properties to realize clinical efficacy against certain ESR1 mutants.Significance: A diversity of activating ESR1 mutations exist, only some of which confer resistance to existing ER antagonists that might be overcome by next-generation inhibitors such as AZD9496. Cancer Discov; 7(3); 277-87. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 235.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Toy W, Weir H, Razavi P, et al. Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discov. 2016. PMID: 27986707. doi:10.1158/2159-8290.CD-15-1523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。